【摘要】 分别表达了rApxⅠr、ApxⅡr、ApxⅢ、rApxⅣr、Apfa和rOMP 6种重组蛋白,以不同组合分组免疫小鼠,分别以APP1型菌(5×109CFU)和APP7型菌(1×1011CFU)进行攻毒。结果显示,试验Ⅱ组(rApxⅠ+rApxⅡ+rApxⅢ+rOMP)的APXⅠ抗体水平、细胞免疫水平及对APP1和APP7型菌的保护效果均显著高于其他各试验组及对照组;试验Ⅰ组(灭活疫苗)、Ⅲ组(rApxⅠ+rApxⅡ+rApxⅢ+rApxⅣ)、Ⅳ组(rApxⅠ+rApxⅡ+rApxⅢ+rApfa)与对照组差异显著,但均显著低于试验Ⅱ组;APXⅠ抗体水平和细胞免疫水平与攻毒保护率呈正相关。证实rApxⅠ+rApxⅡ+rApxⅢ+rOMP组免疫效果最好,可对2个血清型APP的攻击提供有效保护。更多还原

【Abstract】 With recombinant proteins rApxⅠ,rApxⅡ,rApxⅢ,rApxⅣ,rApfa and rOMP against PCP,the BALB/c mice were vaccinated on day 0,14 and 28,respectively.In the vaccinated mice antibody titers were examined every week,and T lymphocyte proliferation and IL-2 production were examined 13,27 and 34 days post-vaccination（PV）.The vaccinated mice were challenged intranasally with serotype 1((5×10⁹CFU)) and serotype 7(1×10¹¹CFU) of Actinobacillus pleuropneumoniae 35 day PV,respectively.In the experimental groupⅡ（rApxⅠ+rApxⅡ+rApxⅢ+rOMP）,the antibody levels against ApxⅠ,T lymphocytes proliferation,IL-2 production,and the protective rates against the above 2 serotypes were significantly higher than those in the experimental groupsⅠ（inactived vaccine）,Ⅲ（rApxⅠ+rApxⅡ+rApxⅢ+rApxⅣ） and Ⅳ（rApxⅠ+rApxⅡ+rApxⅢ+rApfa）,as well as the control.Humoral immunity,cellular immunity and protective efficacy in a low level in the experimental groupsⅠ,Ⅲ and Ⅳ showed that both humoral immunity and cellular immunity had a positive correlation to protective efficacy.The results revealed that the recombinant subunit vaccine containing rApxⅠ+rApxⅡ+rApxⅢ+rOMP provides significant cross protection by simultaneously stimulating both humoral immunity and cellular immunity.更多还原